GR900100716A - The human c3b/c4b receptor (cr1) - Google Patents

The human c3b/c4b receptor (cr1)

Info

Publication number
GR900100716A
GR900100716A GR900100716A GR900100716A GR900100716A GR 900100716 A GR900100716 A GR 900100716A GR 900100716 A GR900100716 A GR 900100716A GR 900100716 A GR900100716 A GR 900100716A GR 900100716 A GR900100716 A GR 900100716A
Authority
GR
Greece
Prior art keywords
fragments
expression
protein
secreted
proteins
Prior art date
Application number
GR900100716A
Other languages
Greek (el)
Inventor
R Gerald Carson
F Michael Concino
T Douglas Fearon
H Stephen Ip
B Lloyd Klickstein
C Savvas Makrides
C Henry Marsh Jr
W Winnie Wong
Original Assignee
Bringham And Women S Hospital
Univ Johns Hopkins
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bringham And Women S Hospital, Univ Johns Hopkins, T Cell Sciences Inc filed Critical Bringham And Women S Hospital
Publication of GR900100716A publication Critical patent/GR900100716A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.
GR900100716A 1989-09-26 1990-09-26 The human c3b/c4b receptor (cr1) GR900100716A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41274589A 1989-09-26 1989-09-26
US07/588,128 US5256642A (en) 1988-04-01 1990-09-24 Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof

Publications (1)

Publication Number Publication Date
GR900100716A true GR900100716A (en) 1992-01-20

Family

ID=27021901

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100716A GR900100716A (en) 1989-09-26 1990-09-26 The human c3b/c4b receptor (cr1)

Country Status (15)

Country Link
US (3) US5256642A (en)
EP (1) EP0502892B1 (en)
JP (1) JP3097753B2 (en)
CN (1) CN1060112A (en)
AT (1) ATE256181T1 (en)
AU (1) AU656312B2 (en)
CA (1) CA2067744C (en)
DE (1) DE69034122D1 (en)
FI (1) FI921291A0 (en)
GR (1) GR900100716A (en)
IE (1) IE903447A1 (en)
IL (1) IL95806A (en)
NZ (1) NZ235445A (en)
PT (1) PT95437B (en)
WO (1) WO1991005047A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
CA2097825A1 (en) * 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
EP1413587A2 (en) * 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US6756211B1 (en) * 1992-05-11 2004-06-29 Corvas International, Inc. Neutropohil inhibitors
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
TW262386B (en) * 1992-09-30 1995-11-11 Senju Pharma Co
GB9301289D0 (en) * 1993-01-22 1993-03-17 Smithkline Beecham Plc Novel composition
ATE223230T1 (en) 1993-02-12 2002-09-15 Avant Immunotherapeutics Inc PULMONARY ADMINISTRATION OF SOLUBLE COMPLEMENT RECEPTOR TYPE 1 SCR1
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
EP0812200B1 (en) * 1993-07-09 2002-02-27 Avant Immunotherapeutics, Inc. Protein purification
US5861272A (en) * 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
FI951778A (en) * 1995-04-12 1996-10-13 Aboatech Ab Oy Method for diagnosing allergies
GB9604518D0 (en) * 1996-03-02 1996-05-01 Smithkline Beecham Plc Novel compounds
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
BR9708387A (en) 1996-03-28 2000-01-04 Genitrix Llc Process for vaccination of a mammal to a selected antigen, host and pathogenic cells, vaccine composition, nucleic acid, and engineered opsonin.
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US6319890B1 (en) * 1996-12-30 2001-11-20 Manfred P. Dierich Inhibition of binding of complement Factor H
US6221621B1 (en) 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
WO1998039659A1 (en) * 1997-03-06 1998-09-11 Bion Diagnostic Sciences, Inc. Screening and treatment using complement regulator or receptor proteins
AU6549398A (en) * 1997-03-10 1998-09-29 Beth Israel Deaconess Medical Center Immune complexes and methods of detection and treatment thereof
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US6503947B1 (en) 1998-01-27 2003-01-07 Brigham And Women's Hospital Method of treating cytotoxic damage
EP3260467A1 (en) * 1998-02-20 2017-12-27 Genentech, Inc. Inhibitors of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20030118983A1 (en) * 2000-03-09 2003-06-26 Cassidy Richard A. Rapid screening procedure for inflammation mediators
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US7109354B2 (en) * 2002-05-28 2006-09-19 3-Dimensional Pharmaceuticals, Inc. Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
PT1549333E (en) 2002-09-20 2012-01-03 Univ Pennsylvania Compstatin analogues with improved activity
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US8124097B2 (en) * 2004-01-21 2012-02-28 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
CN1314811C (en) * 2005-07-25 2007-05-09 中国人民解放军第四军医大学 Recombinant chimeric eucaryotic expression vector Cb1-Grb7(SH2)-RING and use of anti-tumour gene drug
NZ594285A (en) * 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
DK1960422T3 (en) * 2005-11-28 2012-08-13 Univ Pennsylvania VERY EFFECTIVE COMPSTATIN ANALOGS
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
PL1991275T3 (en) 2006-03-08 2015-04-30 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
DE102006019296A1 (en) * 2006-04-26 2007-10-31 Robert Bosch Gmbh Ignition coil for ignition plug in internal combustion engine, has upper and lower strips with reduced breadths in corner areas of inner magnetic core within primary and secondary coil bodies surrounding core
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US8703136B2 (en) 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
CA2667997C (en) * 2006-11-02 2016-10-11 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
CN101611008A (en) * 2006-12-22 2009-12-23 恩希赛弗制药公司 C3A receptor modulators and using method thereof
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
WO2010047793A2 (en) 2008-10-21 2010-04-29 The General Hospital Corporation Cell transplantation
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
EP2453906A4 (en) 2009-07-02 2014-01-15 Musc Found For Res Dev Methods of stimulating liver regeneration
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CA2799192A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
CN103249432A (en) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 Antibodies to the c3d fragment of complement component 3
US10184110B2 (en) 2010-08-06 2019-01-22 The General Hospital Corporation System and apparatus for cell treatment
CN102702339B (en) * 2011-05-24 2013-10-30 华南师范大学 Complement C3 gene, carrier, recombination strain and protein of Epinephelus coioids and application thereof
WO2013036778A2 (en) 2011-09-07 2013-03-14 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
CN108289951A (en) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 Anti- factor D antibody and conjugate
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP4011905A3 (en) 2018-04-06 2022-06-29 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
CA3100071A1 (en) * 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009220A1 (en) * 1988-04-01 1989-10-05 The Johns Hopkins University THE HUMAN C3b/C4b RECEPTOR (CR1)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
EP0028489B1 (en) * 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US4713332A (en) * 1984-01-13 1987-12-15 The Ontario Cancer Institute T cell specific CDNA clone
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
JPH0742235B2 (en) * 1985-11-08 1995-05-10 三共株式会社 Prophylactic / therapeutic agent for autoimmune diseases
AT402153B (en) * 1989-06-26 1997-02-25 Immuno Ag PROTEIN-S CONTAINING PHARMACEUTICAL PREPARATION
IL94522A (en) * 1990-05-28 1994-02-27 Joseph Eldor Device for combined spinal and epidural anesthesia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009220A1 (en) * 1988-04-01 1989-10-05 The Johns Hopkins University THE HUMAN C3b/C4b RECEPTOR (CR1)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLAIMS SEARCHED: ALL *
J. EXP. MED, vol. 168, no. 5, 1st November 1988, pages 1699-1717; L.B. KLICKSTEIN et al.: "Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis" *
J. EXP. MED., vol. 168, no. 4, 1st October 1988, pages 1255-1270; D. HOURCADE et al.: "Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1" *
JOURNAL OF IMMUNOLOGICAL METHODS, vol. 82, no. 2, 1985, pages 303-313; W.W. WONG et al.: "Rapid purification of the human C3b/C4b receptor (CR1) by monoclonal antibody affinity chromatography" *
PROC. NATL. ACAD. SCI. USA, vol. 84, no. 8, April 1987, pages 2459-2463; V.M. HOLERS et al.: "Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Also Published As

Publication number Publication date
EP0502892A4 (en) 1992-11-19
CA2067744C (en) 2001-02-06
FI921291A (en) 1992-03-25
JPH05504053A (en) 1993-07-01
JP3097753B2 (en) 2000-10-10
IL95806A0 (en) 1991-06-30
EP0502892B1 (en) 2003-12-10
IL95806A (en) 1998-04-05
US5256642A (en) 1993-10-26
EP0502892A1 (en) 1992-09-16
PT95437A (en) 1991-08-14
FI921291A0 (en) 1992-03-25
WO1991005047A1 (en) 1991-04-18
US5856297A (en) 1999-01-05
CN1060112A (en) 1992-04-08
US5472939A (en) 1995-12-05
AU6755090A (en) 1991-04-28
CA2067744A1 (en) 1991-03-27
PT95437B (en) 1998-12-31
NZ235445A (en) 1993-02-25
ATE256181T1 (en) 2003-12-15
IE903447A1 (en) 1991-04-10
DE69034122D1 (en) 2004-01-22
AU656312B2 (en) 1995-02-02

Similar Documents

Publication Publication Date Title
IL95806A0 (en) The human c3b/c4b receptor(cr1)
ES2014593A6 (en) THE HUMAN C3b/C4b RECEPTOR (CR1).
Seidman et al. The structure of rat preproatrial natriuretic factor as defined by a complementary DNA clone
US5401651A (en) DNA encoding ENA-78, a neutrophil activating factor
HUT77578A (en) Fibroblast growth factor-10
CA2529179A1 (en) Recombinant adeno-associated virus vector for treatment of alzheimer disease
DK1000146T3 (en) 5 ′ ESTs for non-tissue-specific secreted proteins
KR970705405A (en) Human Chemokine Polypeptides < RTI ID = 0.0 >
Green et al. Identification and characterization of PF4varl, a human gene variant of platelet factor 4
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
CA2062969A1 (en) Recombinantly produced human membrane cofactor protein (mcp)
MX9203654A (en) PURIFICATION, CLONING AND CHARACTERIZATION OF THE GENE FOR INTERLEUKIN I.
PT98695A (en) GENE ENCODER OF NEUROTROPHIC FACTOR FROM LIGACATION TO HEPARIN
CA2342770A1 (en) Ly6h gene
CA2202519A1 (en) Cloning, expression and characterization of a new form of phosphatidylinositol-3-kinase
EP0913470A3 (en) The human C3b/C4b receptor (CR1)
ATE277182T1 (en) THE NUCA PROTEIN OF HAEMOPHILUS INFLUENZAE AND ITS CODING GENE
JP2002519016A (en) Human protein having hydrophobic domain and DNA encoding the same
KR930701475A (en) Human megakaryocyte-colon accelerating factor (hMeg-CSF) and its production method
WO1987007617A1 (en) A novel protein, neuroleukin
EP0353516A2 (en) A method for the preparation of recombinant human beta interleukin-1 in the homogeneous form
KR20010030984A (en) POLYPEPTIDE, cDNA ENCODING THE SAME, AND USE OF THEM
WO1998004692A3 (en) Human neuronatin
JP2002518053A (en) Human glycoprotease-like protein and DNA encoding the same
JP2001519152A (en) Human complement factor H-like protein and cDNA encoding the same

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees